COMP003
41 evidence topics · 2 sources
Objective
Safety, tolerability, and efficacy of COMP360 adjunctive to an SSRI
“This phase II, exploratory, international, fixed-dose, open-label study explored the safety, tolerability, and efficacy of a synthetic form of psilocybin (investigational drug COMP360) adjunct to a selective serotonin reuptake inhibitor in participants with TRD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With the development of psilocybin specifically as a treatment for TRD, it is important to test the impact of chronic antidepressant treatment on the antidepressant effects of psilocybin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This outcome will inform whether it is necessary to withdraw people from antidepressant drugs prior to administering psilocybin for a safe or therapeutic effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study period and sites in Ireland and the United States
“This was a phase II, exploratory, fixed-dose, open-label study conducted between August 2020 and September 2021.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The protocol was approved by ethics committees at two sites located in Ireland and the United States (US): the Clinical Research Ethics Committee of the Cork Teaching Hospitals (CREC), and the Advarra Center for IRB Intelligence (CIRBI).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry dates and locations
| Field | Registry entry |
|---|---|
| Study start (actual) | “2020-08-10” |
| Primary completion (actual) | “2021-10-14” |
| Study completion (actual) | “2021-10-14” |
| United States site | “Kadima Neuropsychiatry Institute” |
| Ireland site | “Sheaf House, Tallaght Hospital” |
Study design
Open-label, single-arm, fixed-dose design
“This trial explored the safety and efficacy of a single dose of 25 mg of the investigational drug COMP360, a proprietary pharmaceutical-grade synthetic psilocybin formulation, optimized for stability and purity, adjunct to an antidepressant drug in participants experiencing a current episode of treatment-resistant MDD (EudraCT number: 2018 002377; Clinicaltrials.gov identifier: NCT04739865).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“COMP360 was supplied by the sponsor, COMPASS Pathfinder Ltd (a subsidiary of COMPASS Pathways plc), London, UK.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The sponsor supervised the study which was conducted by a contract research organization (Worldwide Clinical Trials, Nottingham, UK, and North Carolina, US).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Screening, administration, and follow-up periods
“Eligible participants entered the screening period and attended the clinic weekly for three weeks prior to the psilocybin administration session.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were followed up for three weeks to monitor safety and efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recruitment alongside the phase 2b trial
“Participants entered this study having been previously pre-screened for our phase IIb clinical trial (COMP 001), which was not an open label study, and the current trial (COMP 003) simultaneously.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In COMP 001, 428 patients were screened and 233 were found to be eligible and underwent randomization having successfully withdrawn from any antidepressant drug as required by the protocol.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients unable or unwilling to complete medication withdrawal at the two participating sites, or those who had a preference to be screened for COMP 003 instead, were considered for this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Inclusion criteria: treatment-resistant episode of major depressive disorder
“This study recruited adults aged 18 years or older who were outpatients and referred by practitioners from specialized psychiatric services or word of mouth from primary care services.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were experiencing TRD, defined by meeting the Diagnostic and Statistical Manual of Mental Disorders (5th edition) criteria of single or recurrent episode of MDD (if first single episode, duration >3 months ≤2 years was required) without psychotic features and with at least moderate symptom severity (Hamilton Depression Rating Scale, 17 item [HAM-D-17] >18) at Screening and Baseline, and having failed to respond to an adequate dose and duration (>8 weeks) of two to four pharmacological treatments for the current episode, including their current SSRI” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inclusion criteria: stable treatment with a single SSRI
“Participants were taking a locally approved therapeutic dose of a single SSRI with at least 75% adherence for a minimum of six weeks prior to taking part and were asked to continue this treatment for the duration of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Permitted SSRIs included citalopram, escitalopram, fluoxetine, paroxetine, sertraline, vilazodone, and vortioxetine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion criteria: psychiatric comorbidity, suicide risk, and other antidepressants
“Participants taking multiple antidepressant therapies were excluded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants experiencing a major comorbid psychiatric disorder or suicide risk were excluded based on clinical assessment, medical records, the Mini International Neuropsychiatric Interview (version 7.0.2), the McLean screening instrument for borderline personality disorder, and the Columbia-Suicide Severity Rating Scale (C-SSRS)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion criteria in the registry record
Treatment
Single 25 mg dose during a monitored session
“The administration session (Day 1) consisted of a single administration of psilocybin 25 mg which could be administered to up to six participants in different rooms simultaneously.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Each participant was accompanied by a lead therapist, with whom they had completed preparation, for the six- to eight-hour session to ensure physical and psychological safety and encourage the participant to remain attentive to the natural unfolding of their subjective experience, while avoiding active guidance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An assisting therapist was available within the vicinity to step in at any time if the lead therapist needed to leave or additional support was required, and a study psychiatrist was on site.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Blood pressure was monitored continuously using a finger cuff device.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants wore eyeshades and headphones with a specifically designed playlist of music to assist in directing their attention internally.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preparation and integration sessions
“Preparation for the psilocybin experience was conducted by a therapist who was trained by the sponsor through a specially devised program” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Preparation took place over three sessions, during which the therapist built trust with the participant, explained the trial design and procedures, provided psychoeducation, and helped to prepare the participant for the psilocybin experience.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At Day 2 and Week 1 following administration, participants completed an integration session with their lead therapist who encouraged them to derive their own solutions and insights from the psilocybin experience.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Continued SSRI treatment and simultaneous sessions
“All participants continued their SSRI medication throughout the follow-up period and to the end of the study (Week 3); two participants on escitalopram increased their dose (10–20 mg) during the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two psilocybin administration sessions (Day 1) involved simultaneous administration, where two participants were administrated at the same time (in separate rooms) in each session.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using montgomery-åsberg depression rating scale total score as the primary endpoint
Primary endpoint definition and scale range
“The primary efficacy end point was the change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from Baseline (Day -1) to three weeks post-psilocybin administration (Week 3)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Total scores in the MADRS range from 0-60, with higher scores indicating greater severity of depression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Remote blinded independent rating
“The MADRS was administered by a remote, blinded independent rater, following the structured interview guide” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“at Baseline (Day -1), Day 2 and Weeks 1, 2, and 3 to ensure standardization of administration and questions (service was provided by Worldwide Clinical Trials).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary endpoints: response, remission, and clinician global ratings
“Key secondary end points included the proportion of participants with a response (defined as a ≥50% improvement in MADRS total score from Baseline) and remission (defined as a MADRS total score ≤10) at Week 3, change from Baseline in Clinical Global Impression–Severity (CGI-S) score at Week 3” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The CGI-S is a 7-point rating scale of severity based on clinical judgment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
No formal sample size calculation
“No formal sample size calculations were performed for this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nineteen participants were dosed and the mean Baseline MADRS total score was 31.7 (SD = 5.77).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry enrollment
| Field | Registry entry |
|---|---|
| Enrollment (actual) | “19” |
Description of analysis sets
Safety, full analysis, and per-protocol sets
“Safety analyses were performed on the safety analysis set which included all participants who received psilocybin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Efficacy analyses were performed on the full analysis set which included all participants who received psilocybin and had at least one post-Baseline efficacy assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All enrolled participants were included in the safety and full analysis sets and one participant was excluded from the per- protocol analysis set due to violation of exclusion criterion two: Prior electroconvulsive therapy and/or ketamine for current episode” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descriptive analysis and missing data
“There was no imputation for missing efficacy data and the observed data were used in statistical analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary efficacy end point (change from Baseline to Week 3 in the MADRS total score) was evaluated with the use of descriptive summaries using statistics for continuous variables.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, the secondary and exploratory efficacy end points were also summarized descriptively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Enrolled, dosed, and completed
“Nineteen out of 24 enrolled participants with TRD were dosed and completed the study - there were no post-treatment withdrawals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The stable and ongoing SSRIs included sertraline, escitalopram, fluoxetine, vilazodone, paroxetine, and citalopram” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Demographic and clinical characteristics, safety analysis set
Depression severity and episode duration at baseline
“The length of current episode of depression was greater than one year for 84.2% of participants, and 36.8% had experienced 3 or 4 treatment failures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At Baseline the MADRS total score was classified as severe (total score ≥31) for 57.9% of participants and the mean MADRS total score was 31.7 (SD = 5.77)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At Baseline the mean CGI-S score was 4.3 (SD = 0.99) which falls into the ‘moderately ill’ range (score = 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Primary endpoint: MADRS change from baseline at Week 3
“The mean MADRS total score at Week 3 was 16.8 (95% confidence interval [CI], 11.2–22.4) which equated to a clinically meaningful mean change from Baseline of −14.9 (95% CI, −20.7 to −9.2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This improvement was apparent at Day 2 and maintained throughout the three-week follow-up” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The results from per-protocol analysis of the primary end point were consistent with the full analysis set.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A reduction in every item in the MADRS was apparent from Baseline to Week 3” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MADRS response and remission
“Response (≥50% reduction from Baseline MADRS total score) at Week 3 was evident in eight (42.1%) participants and was sustained throughout the follow-up period for 63.2% at Day 2, and 57.9% at Weeks 1 and 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The same 42.1% of participants who were responders at Week 3 were also remitters (MADRS total score of ≤10) at Week 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Remission rates remained high throughout the follow-up period for 52.6% at Day 2, 47.4% at Week 1, and 42.1% at Week 2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinician global impression of severity and improvement
“The mean CGI-S score at Week 3 was 2.9 (SD = 1.84) which equates to a −1.3 (SD = 1.29) change from Baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Proportion of responders on the CGI-S were 42.1% at Day 2, 63.2% at Week 1, 57.9% at Week 2, and 52.6% at Week 3” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fourteen participants (73.7%) were considered at least minimally improved (CGI-I score ≤3) by clinicians from Baseline to Week 3 and seven participants (36.8%) were considered responders (score or 1 or 2) at Week 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Authors' comparison with the phase 2b trial
“in fact, the response and remission rates were higher in the current study (42% response and remission rates at Week 3 verses 37% and 29%, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This indicates that antidepressant drug withdrawal is not a prerequisite for a therapeutic response to psilocybin in this patient group, despite most previous trials including withdrawal as a standard procedure” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Acute psychedelic experience on the Five-Dimensional Altered States of Consciousness questionnaire
“Alterations of consciousness on the 5D-ASC were observed in every dimension including visual restructuralization, oceanic boundlessness, reduction of vigilance, and to a lesser extent anxious ego dissolution and auditory alterations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Health-related quality of life: EQ-5D-3L and EQ-VAS
“Participants’ EQ-5D-3L mean total score at Baseline was 0.51 (SD = 0.333) and improved by an average of 0.18 (SD = 0.310) by Week 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The EQ-VAS mean score at Baseline was 49.0 (SD = 17.45) and improved by an average of 13.7 (SD = 18.09) by Week 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Self-reported depression: QIDS-SR-16
“The QIDS-SR-16 mean total score at Baseline was 16.5 (SD = 5.04), indicating severe depression, and decreased by an average of 6.9 (SD = 6.05) by Week 3 where the mean total score indicated mild depression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anxiety and affect: GAD-7 and PANAS
“The GAD-7 mean total score at Baseline was 12.9 (SD = 5.94) and decreased by an average of 4.1 (SD = 4.90) by Week 3, which is considered a clinically meaningful improvement in anxiety symptoms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean Baseline score for positive affect was 19.3 (SD = 7.22) and increased by an average of 8.1 (SD = 10.58) by Day 2, and mean Baseline score for negative affect was 24.3 (SD = 10.26) and decreased by an average of 7.5 (SD = 6.79) by Day 2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Treatment-emergent adverse events from Day 1 to Week 3, safety analysis set
Onset, duration, and headache
“Seventeen TEAEs were reported for 12 participants (63.2%), none of which were considered serious, or led to study withdrawal” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eleven of these TEAEs, which were experienced in nine participants (47.4%), had an onset of Day 1 (psilocybin administration day), and eight resolved on the same day.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common TEAE reported was headache (six events; six participants [31.6%]) which had an onset of Day 1 (n = 4) or Day 2 (n = 2) which were predominantly transient, reported as mild and moderate in five and one participants, respectively, and resolved on their own or with standard medication (paracetamol and ibuprofen) on the same day or day after.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All TEAEs resolved before the end of the study (Week 3), and none had a duration exceeding seven days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blood pressure increase treated with clonidine
“Three participants had a TEAE of blood pressure increased which were considered related or possibly related to study treatment, two were severe and treated with clonidine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One of these patients experienced chest heaviness and headache (also relieved by clonidine).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no specific parameters for administering clonidine and it was down to investigator discretion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Suicidal ideation and behavior
“There were no reports of active suicidal ideation with plan or intent to act, attempts, or self-injurious behavior at Baseline or during the study and follow-up period” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the follow-up period, one participant who was disappointed by their lack of response and quality of psychedelic experience invoked concern regarding their mental state during a conversation with their non-study therapist, which prompted the therapist to initiate an involuntary assessment of the participant at a local emergency department.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After evaluation by a psychiatrist in the emergency department, the participant was deemed to not be a danger to themselves and not in need of hospital admission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Laboratory tests and electrocardiograms
“There were no clinically meaningful shifts from Baseline in clinical laboratory tests.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No participant had treatment-emergent clinically important ECG values or increases in QTcF interval from Baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: open-label single-arm design, small sample, short follow-up, blood pressure measurement, sponsor analysis
The authors state that the study was limited by its small size, open-label design and absence of a comparator, a sample that was not demographically diverse, and the exclusion of participants with high suicide risk or current hospitalization, and that the open-label design may have influenced participant expectations. Nineteen participants were dosed, no formal sample size calculation was performed, efficacy was summarized descriptively, and follow-up lasted three weeks. Blood pressure elevations were recorded with a finger cuff system that was not accurately calibrated. The sponsor performed the data review, interpretation, and post hoc analyses, and several authors are current or past employees of COMPASS Pathfinder. The authors state that the findings need confirmation in a larger, double-blind, comparator-controlled study.
Authors' stated limitations
“The present study was limited by its small size, open-label design and absence of a comparator, the lack of a demographically diverse sample, and the exclusion of participants with high suicide risk or current hospitalization.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is possible that the open-label design influenced participant bias and expectations towards the study treatment, and definitive comparisons with studies that included a withdrawal from SSRIs is not necessarily valid.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The findings will need to be confirmed in a larger, double-blind, comparator-controlled study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blood pressure measurement
“Unfortunately, we cannot give an accurate measure of the blood pressure elevation that undoubtedly occurred, because the finger cuff system was not accurately calibrated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“but these specific instances were recorded with a system which may not have been properly calibrated and were not checked by conventional cuff auscultation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor role in analysis and interpretation
“Review of the data, interpretation, and post-hoc statistical analyses and were performed by the sponsor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“GMG, MC, LM, SM, HS, CS, SCS, JT, SW, and EM are current or past employees of COMPASS Pathfinder.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote